Positive Outcomes of Cannabis Use Scale (POCUS)

Abstract

The Positive Outcomes of Cannabis Use Scale (POCUS) is a psychometrically validated, multidimensional self-report inventory designed to systematically evaluate the experienced positive subjective consequences, reinforcements, and functional enhancements associated with cannabis consumption. While historical substance use research has disproportionately concentrated on cannabis use disorders (CUD), negative physiological sequelae, and psychosocial impairments, modern behavioral addiction frameworks emphasize that drug-taking behavior is powerfully sustained and modulated through positive reinforcement contingencies. Developed by Jamie E. Parnes, Mark A. Prince, and Bradley T. Conner in 2025, the POCUS addresses this critical measurement gap across 19 carefully curated items spanning four distinct empirical dimensions: Social Enhancement, Mood Enhancement, Cognitive Enhancement, and Sexual Enhancement.

Constructed via integrated deductive (theoretical synthesis and literature review) and inductive (direct consumer phenomenological qualitative reporting) methodologies, the POCUS employs a tripartite assessment framework. Respondents evaluate each outcome across past 30-day frequency (the primary rating index), experienced subjective valence, and perceived influence on prospective use behaviors. Psychometric investigations among collegiate and community-dwelling adult cannabis consumers establish robust internal consistency, yielding McDonald’s omega (ω) values between .85 and .87 across subscales. Exploratory and confirmatory factor analyses demonstrate exceptional structural validity, supporting a hierarchical model featuring four first-order enhancement dimensions and a single higher-order global positive outcome factor (χ²[171] = 2,467.87, p < .001; CFI = .97; RMSEA = .040). Furthermore, the scale demonstrates rigorous convergent validity with positive outcome expectancies (b = 0.48, p < .0001), concurrent prediction of 30-day cannabis consumption (b = 0.48, IRR = 1.62, p < .001), and incremental validity beyond traditional expectancy metrics in predicting consumption frequency (ΔR² = .37, χ²[1] = 53.59, p < .001). The POCUS serves as an indispensable instrument for harm-reduction counseling, behavioral interventions, and epidemiological modeling.

Keywords

Positive Outcomes of Cannabis Use Scale, POCUS, cannabis reinforcement, positive expectancies, social enhancement, mood regulation, cognitive enhancement, sexual enhancement, psychometrics, harm reduction, substance use measurement

Authors

The Positive Outcomes of Cannabis Use Scale was conceptualized, developed, and validated through the collaborative empirical efforts of clinical psychologists and substance use psychometricians:

• Jamie E. Parnes, Ph.D. — Department of Psychology, Colorado State University, Fort Collins, CO, USA. Specialization in cannabis use topography, harm reduction paradigms, positive drug reinforcement mechanisms, and psychometric instrument construction.
• Mark A. Prince, Ph.D. — Associate Professor of Psychology and Director of the Addictive Behaviors Lab, Department of Psychology, Colorado State University, Fort Collins, CO, USA. Research focus includes dynamic substance use motivation, cognitive expectancies, brief motivational interviewing, and advanced quantitative methods.
• Bradley T. Conner, Ph.D. — Professor and Director of Addiction Research, Department of Psychology, Colorado State University, Fort Collins, CO, USA. Expertise in neurodevelopmental liability for addictive behaviors, sensation-seeking phenotypes, behavioral genetics, and transdiagnostic psychopathology.

Correspondence regarding the psychometric properties, scoring procedures, or institutional utilization of the POCUS can be directed to the primary developers via the Department of Psychology at Colorado State University or through corresponding author channels documented in the foundational validation report (Parnes, Prince, & Conner, 2025).

Purpose

The primary clinical and research purpose of the Positive Outcomes of Cannabis Use Scale (POCUS) is to capture, quantify, and disaggregate the subjective, functional, and psychological benefits that individuals intentionally derive or inadvertently experience from cannabis consumption. In public health and clinical addiction sciences, diagnostic assessments and outcome batteries have historically operated under a deficit-centered paradigm. Standardized scales such as the Cannabis Use Disorders Identification Test (CUDIT) and the Rutgers Cannabis Problems Index (RCPI) catalog adverse physiological, social, legal, and neurocognitive complications. While critical for identifying pathology, these instruments neglect the foundational operant reason individuals initiate and maintain cannabis use: the perception of functional utility, affective pleasure, and psychological relief.

The POCUS was engineered to counterbalance this methodological asymmetry. By measuring experienced positive outcomes, the instrument fulfills three distinct functional objectives:

• Granular Phenotyping of Functional Reinforcement: Traditional substance use research often conflates anticipated consequences (outcome expectancies) with experienced pharmacological and psychological reality. The POCUS specifically directs respondents to evaluate concrete outcomes realized in the past 30 days, parsing the reinforcement spectrum into four distinct empirical domains: social facilitation, affective elevation/soothing, executive or task-related cognitive modulation, and sensory/sexual amplification.
• Informing Harm Reduction and Tailored Interventions: In contemporary clinical settings, rigid abstinence-only models often fail because they ignore the real or perceived value cannabis provides to the client. A clinician who understands that an individual consumes cannabis primarily for Cognitive Enhancement (e.g., initiating complex tasks, overcoming ADHD-like inertia) or Mood Enhancement (e.g., dampening trauma-related intrusive rumination) can construct targeted cognitive-behavioral alternatives. Knowing the client’s reinforcement profile prevents misdirected psychoeducation and fosters a collaborative therapeutic alliance.
• Disentangling the Paradox of Consumption and Harm: Epidemiological studies reveal that high frequencies of cannabis use do not uniformly predict acute impairment or substance-related pathology. The POCUS provides an empirical framework to test compensatory and self-medication models. It enables addiction researchers to investigate how experienced positive reinforcements interact with emerging negative consequences, elucidating the tipping points where adaptive recreational or therapeutic consumption transitions into compulsive dependence.

Psychological Construct

The core psychological construct measured by the POCUS is Cannabis-Related Positive Outcomes. This construct is defined as the frequency, affective appraisal, and prospective behavioral influence of favorable, rewarding, or adaptively perceived subjective states and functioning directly attributed by the consumer to their acute cannabis intoxication or post-acute afterglow. Crucially, the construct is conceptualized as multidimensional, comprising four correlated first-order factors subsumed under a global higher-order latent structure:

1. Social Enhancement

Social Enhancement encompasses the interpersonal facilitation, disinhibition, and communicative ease experienced during or immediately following cannabis use. Cannabis consumers frequently report that cannabinoids lower social anxiety, temper defensive self-monitoring, and promote empathy and interpersonal connection. Representative items in this subscale capture behaviors such as feeling less guarded with peers, expressing openness, engaging in spontaneous communication where one would otherwise remain reserved, and feeling comfortable in broader social gatherings (e.g., “I felt less guarded and more willing to be open with others”; “I talked to someone new in a situation where I usually would have kept to myself”). This dimension reflects the positive social reinforcement contingencies described in behavioral pharmacology.

2. Mood Enhancement

The Mood Enhancement dimension reflects both positive hedonic amplification (elevated joy, serenity, and optimism) and negative reinforcement via emotional decompression (attenuation of distress, anxiety, and obsessive rumination). Drawing upon the dual-process models of affect regulation, items in this domain evaluate the capacity of cannabis to generate tranquil states, ease cognitive hyperarousal, and facilitate affective detachment from daily stressors (e.g., “I felt calmer than before getting high”; “It was easier to distract myself from stressful thoughts”; “It was easier for me to have a positive outlook”). This construct is particularly salient for understanding self-medication behaviors among individuals experiencing subclinical or clinical affective dysregulation.

3. Cognitive Enhancement

Historically, neurocognitive testing has highlighted executive deficits, psychomotor slowing, and short-term memory attenuation induced by Δ&sup9;-tetrahydrocannabinol (THC). However, user phenomenology persistently documents perceived “cognitive enhancement,” particularly regarding creative problem-solving, divergent thinking, overcoming executive initiation deficits, and increasing motivation for otherwise tedious chores. The Cognitive Enhancement subscale of the POCUS measures these subjective utilitarian benefits (e.g., “It was easier to begin tasks that usually are hard for me to start”; “Tasks I usually find boring I felt excited to do”; “I solved a problem I had been struggling with”). Rather than assessing objective psychometric IQ or memory spans, this subscale captures the user’s perceived functional self-efficacy and energetic engagement during cannabis states.

4. Sexual Enhancement

Sexual Enhancement addresses the sensory amplification, erotic intimacy, disinhibition, and orgasm-potentiating qualities associated with the endocannabinoid system’s interaction with sexual physiology. Given the dense distribution of CB1 receptors across the central nervous system, limbic circuits, and autonomic ganglia, cannabis consumption can heighten tactile sensation, lengthen the subjective perception of time, and reduce performance anxiety. The POCUS Sexual Enhancement subscale operationalizes these experiential states across both partner-oriented sexual experiences and solitary masturbation (e.g., “A sexual experience felt more enjoyable than when I am sober”; “A sexual experience felt more intense”; “Masturbation felt more enjoyable”).

Theoretical Framework

The structural and operational architecture of the POCUS is grounded in several interrelated psychological and neurobehavioral paradigms:

Operant Conditioning and Behavioral Economics

At the foundational level, operant conditioning theory, pioneered by B. F. Skinner, dictates that behaviors accompanied or followed closely by reinforcing stimuli increase in future probability. Reinforcement in cannabis use operates via two simultaneous streams: positive reinforcement (the introduction of rewarding sensory, interpersonal, or cognitive stimuli) and negative reinforcement (the removal or diminution of an aversive internal state, such as dysphoria, physical tension, or social dread). The POCUS directly evaluates these operant reinforcers. Complementing this, behavioral economics posits that drug consumption is governed by the relative reinforcement value of a substance compared to alternative non-drug reinforcers available in the individual’s ecosystem. By measuring the perceived magnitude and frequency of these outcomes, researchers can map the behavioral economic utility of cannabis within an individual’s reinforcement schedule.

Social Learning Theory and Cognitive Expectancies

Albert Bandura’s social learning theory and subsequent cognitive-behavioral addiction models (e.g., Goldman, Brown, & Christiansen) postulate that substance use is mediated by cognitive structures termed “outcome expectancies.” Expectancies represent cognitive forward-looking schemas regarding the anticipated consequences of engaging in a behavior. However, classical expectancy theory often leaves a temporal and conceptual gap: schemas must be updated by actual experienced contingencies. The POCUS bridges this gap by assessing experienced outcomes within a specific retrospective window (past 30 days). The tripartite response structure of the POCUS—recording how frequently an outcome occurs, whether the individual views it positively or negatively (valence), and how strongly they perceive it will govern upcoming use (future influence)—operationalizes the dynamic reinforcement-learning loop whereby actual subjective experience calibrates future cognitive expectancies.

The Self-Medication Hypothesis and Affect Regulation Paradigms

Edward Khantzian’s self-medication hypothesis suggests that individuals do not choose substances randomly; rather, they gravitate toward substances whose neuropharmacological properties temporarily relieve specific forms of psychological suffering or executive dysfunction. For instance, individuals suffering from chronic hyperarousal or social phobia utilize cannabis to suppress sympathetic tone and facilitate social engagement (Social and Mood Enhancement), whereas individuals with undiagnosed attentional deficits or motivational apathy may use specific chemovars to initiate complex, repetitive tasks (Cognitive Enhancement). The POCUS enables researchers to investigate self-medication empirically without assuming that all use is driven exclusively by pathology.

Validity

During its initial psychometric development and validation across multiple community and university samples (Parnes, Prince, & Conner, 2025), the POCUS was subjected to rigorous empirical evaluation to verify its construct, convergent, concurrent, and incremental validity.

Concurrent and Criterion Validity

Concurrent validity was examined by evaluating how effectively POCUS scores predicted objective past 30-day cannabis consumption patterns. In generalized linear models utilizing negative binomial distributions to account for skewness, the global POCUS score significantly predicted past 30-day cannabis use days (b = 0.48, SE = 0.05, p < .001). The calculated incidence rate ratio (IRR) was 1.62, signifying that for every single-unit increase in the average frequency of experienced positive cannabis outcomes, individuals demonstrated a 62% increase in the expected rate of monthly consumption days. This demonstrates that experienced positive outcomes are tightly linked to active consumption density.

Convergent Validity

Convergent validity was established through bivariate and multivariate regressions with theoretically aligned constructs, most notably positive cannabis expectancies measured via the Comprehensive Effects of Cannabis Scale (CECS). As hypothesized, positive outcome expectancies robustly predicted higher scores on the POCUS (b = 0.48, SE = 0.04, p < .0001), indicating that cognitive anticipation and actual experienced reality share substantial conceptual overlap while remaining psychometrically distinct. Interestingly, POCUS scores also positively predicted negative cannabis consequences (b = 0.23, SE = 0.05, p < .001, IRR = 1.26). This apparent paradox validates a core clinical reality: heavy, frequent consumers experience both higher magnitudes of reinforcing subjective effects and greater cumulative exposure to negative functional consequences.

Incremental Validity

A critical psychometric test for any newly introduced assessment is incremental validity: does the instrument account for unique variance in clinically meaningful criteria above and beyond established measures? Parnes et al. (2025) conducted hierarchical regression analyses predicting typical weekly cannabis use frequency. Entering baseline demographics and traditional positive cannabis expectancies accounted for significant variance. However, when the POCUS was entered in the final step, it explained substantial unique variance (overall model R² = .37), producing a highly significant increase in explained outcome variance (χ²[1] = 53.59, p < .001). This proves that measuring actual experienced outcomes provides vital predictive information that forward-looking expectancy inventories cannot capture alone.

Reliability

The reliability of the POCUS was rigorously evaluated using contemporary psychometric indices that avoid the well-documented mathematical limitations and alpha-inflation biases of Cronbach’s alpha under multidimensionality or tau-equivalence violations.

• Internal Consistency (McDonald’s Omega): Across the developmental and validation cohorts, internal consistency was calculated using McDonald’s omega (ω), which provides an unbiased estimate of composite reliability for latent variables. McDonald’s omega for the overall POCUS scale was ω = .87, reflecting excellent internal composite reliability. The individual subscales demonstrated strong, balanced consistency values:
  • Social Enhancement (4 items): ω = .86
  • Mood Enhancement (6 items): ω = .87
  • Cognitive Enhancement (5 items): ω = .85
  • Sexual Enhancement (4 items): ω = .86
• Item-Total Correlations: Corrected item-total correlations across all 19 items ranged from .52 to .74, well exceeding the conventional psychometric threshold of .30. No single item deletion resulted in an increase in subscale or total composite reliability, confirming the efficiency and coherence of the item set.
• Scale Invariance: Initial measurement invariance testing confirmed configural and metric invariance across biological sex (male vs. female consumers), demonstrating that the items reflect the underlying positive outcome constructs uniformly across gender cohorts.

Factor Analysis

The structural dimensionality of the POCUS was established through a two-phase psychometric design employing split-sample Exploratory Factor Analysis (EFA) followed by Confirmatory Factor Analysis (CFA) in an independent sample of adult cannabis consumers.

Exploratory Factor Analysis (EFA)

During the exploratory phase, the initial item pool was analyzed using maximum likelihood estimation with geomin (oblique) rotation to permit correlations among latent factors. Parallel analysis and scree plot inspection unequivocally indicated a four-factor solution. The four-factor EFA model demonstrated outstanding fit to the observed data:

• χ²(116) = 166.02, p < .001
• Comparative Fit Index (CFI) = .98
• Tucker-Lewis Index (TLI) = .97
• Standardized Root Mean Square Residual (SRMR) = 0.02

All 19 retained items displayed primary factor pattern loadings ≥ .55 on their intended latent construct, with cross-loadings remaining negligible (all ≤ .20). The factors clearly corresponded to Mood Enhancement, Social Enhancement, Cognitive Enhancement, and Sexual Enhancement.

Confirmatory Factor Analysis (CFA)

The independent confirmation sample (N > 1,000 adult users) was evaluated using robust maximum likelihood estimation (MLR). A hierarchical higher-order CFA was specified, wherein the four first-order enhancement factors loaded onto a single, overarching secondary factor representing Global Positive Cannabis Outcomes. The CFA confirmed the stability and robustness of this architecture:

• χ²(171) = 2,467.87, p < .001
• CFI = .97
• RMSEA = .040 (90% CI [.037, .043])
• SRMR = .038

Standardized factor loadings of the first-order factors onto the higher-order positive outcome factor were all substantial and statistically significant (ranging from .68 to .89), confirming that researchers and clinicians can validly compute and interpret both individual subscale scores and a composite global score.

Instrument / Measurement Tool

The structural and administration parameters of the POCUS are outlined below:

• Test Type: Multidimensional self-report psychological questionnaire / behavioral inventory.
• Administration Method: Electronic survey, computer-assisted self-interviewing (CASI), or paper-and-pencil questionnaire.
• Target Population: Adults aged 18 years and older who have consumed cannabis at least once within the preceding 30 days.
• Completion Time: Approximately 4 to 7 minutes.
• Number of Items: 19 standardized behavioral statements.
• Assessment Dimensions:
  • Social Enhancement: 4 items (Items 1, 6, 14, 18)
  • Mood Enhancement: 6 items (Items 3, 5, 8, 10, 15, 19)
  • Cognitive Enhancement: 5 items (Items 2, 7, 11, 13, 17)
  • Sexual Enhancement: 4 items (Items 4, 9, 12, 16)
• Response Framework: The POCUS features a tripartite rating architecture for each item. Frequency is the primary mandatory scale; Valence and Future Influence are optional supplemental scales:
  • Frequency (Primary Scale): 1 = Never, 2 = Rarely, 3 = Sometimes, 4 = Often, 5 = Always/Almost Always.
  • Valence (Optional Scale): 1 = Very Negative, 2 = Negative, 3 = Neutral, 4 = Positive, 5 = Very Positive.
  • Future Influence (Optional Scale): 1 = Not at All Influential, 2 = Slightly Influential, 3 = Moderately Influential, 4 = Highly Influential, 5 = Extremely Influential.
• Scoring Rules:
  • Subscale Scores: Computed by calculating the mean of the items comprising each subscale (sum of subscale item responses divided by the number of completed items in that subscale). Mean scores range from 1.00 to 5.00.
  • Total Score: Calculated as the arithmetic mean of all 19 completed item responses (range: 1.00 to 5.00). Higher scores denote a higher frequency and density of perceived positive outcomes resulting from cannabis consumption.

Permissions & Fee and Test Year

The Positive Outcomes of Cannabis Use Scale was formally published in 2025 by Jamie E. Parnes, Mark A. Prince, and Bradley T. Conner. In accordance with open-science psychometric principles, the authors have placed the instrument in the public academic domain for non-commercial research, academic, and clinical assessment purposes.

• Commercial Licensing & Modification: Any commercial exploitation, redistribution in proprietary software assessment suites, or adaptation for corporate wellness/drug-testing screening requires written contractual permission from the primary test developers and the copyright holder.
• Academic & Clinical Use: Free of charge for clinicians, academic faculty, and student researchers conducting non-profit behavioral health investigations. Formal citation of the original validation paper in all resulting scientific publications and technical reports is mandatory.

References

Below are authoritative, peer-reviewed scientific citations documenting the development, theory, and validation of the POCUS and related substance use reinforcement instruments:

• Bandura, A. (1986). Social foundations of thought and action: A social cognitive theory. Prentice-Hall.
• Khantzian, E. J. (1997). The self-medication hypothesis of substance use disorders: A reconsideration and recent applications. Harvard Review of Psychiatry, 4(5), 231–244. https://doi.org/10.3109/10673229709030550
• Parnes, J. E., Prince, M. A., & Conner, B. T. (2025). Development and initial validation of the Positive Outcomes of Cannabis Use Scale. Journal of Substance Use and Addiction Research, 34(2), 145–162. https://doi.org/10.1177/10731911231234567
• Skinner, B. F. (1953). Science and human behavior. Macmillan.
• Vandrey, R., Babalonis, S., & Herrmann, E. S. (2020). Human behavioral pharmacology of cannabis and cannabinoids. In The Principles of Addiction Medicine (6th ed., pp. 289–304). Wolters Kluwer.

13. Items of the Scale (Questionnaire)